Evidence map›Paper›PMID 39502014›Full record

ArticlePediatric blood & cancer2025

Outcomes of patients with intermediate-risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531.

Julie Voeller, Howard M Katzenstein, Arlene Naranjo, Sheena C Tenney, Lulu Chen, Wendy B London, Michael H Handler, Mary Lou Schmidt, Hiroyuki Shimada, Michael D Hogarty and 6 more

Abstract read
In one paragraph

Article in Pediatric blood & cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Julie VoellerDepartment of Pediatrics, CHRISTUS Children's, Baylor College of Medicine, San Antonio, Texas, USA.ORCID https://orcid.org/0000-0001-7811-513X
Howard M KatzensteinDepartment of Pediatrics, Nemours Children's Hospital, Wilmington, Delaware, USA.
Arlene NaranjoChildren's Oncology Group Statistics & Data Center, Department of Biostatistics, University of Florida, Gainesville, Florida, USA.
Sheena C TenneyChildren's Oncology Group Statistics & Data Center, Department of Biostatistics, University of Florida, Gainesville, Florida, USA.
Lulu ChenChildren's Oncology Group Statistics & Data Center, Department of Biostatistics, University of Florida, Gainesville, Florida, USA.
Wendy B LondonDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0003-3571-6538
Michael H HandlerDepartment of Neurosurgery, Children's Hospital Colorado, Aurora, Colorado, USA.
Mary Lou SchmidtDepartment of Pediatrics, University of Illinois at Chicago College of Medicine, Chicago, Illinois, USA.
Hiroyuki ShimadaDepartment of Pathology, Lucile Packard Children's Hospital, Stanford University, Palo Alto, California, USA.
Michael D HogartyChildren's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Julie Gastier-FosterDepartment of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Julie R ParkDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Susan L CohnDepartment of Pediatrics, University of Chicago, Chicago, Illinois, USA.
John M MarisChildren's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-8088-7929
Rochelle BagatellChildren's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-5729-8819
Clare J TwistDepartment of Pediatrics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomesR35CA220500 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI JOHN M MARIS · 2017 to 2026
$8.7M
NCI NIH HHS R35 CA220500NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899St. Baldrick's Foundation
6 · The paper itself

Abstract

backgroundTumor invasion of the spinal canal is detected radiographically in approximately 15% of patients with newly diagnosed neuroblastoma (NB). The optimal clinical approach to maintain excellent survival outcomes while minimizing long-term sequelae is yet to be defined.

methodsPatients with intermediate-risk neuroblastoma (IR-NB) and radiographically identified intraspinal tumors who were treated on the Children's Oncology Group study ANBL0531 were studied prospectively to evaluate neurologic outcomes related to cord compression. Patients were defined as being symptomatic versus asymptomatic based on reporting of neurologic motor deficits at diagnosis. Patient characteristics, tumor biology, chemotherapy treatment, surgical interventions, and neurologic and disease outcomes are reported.

resultsOf the 92 patients with intraspinal tumors, 42 (46%) were symptomatic and most (73%) had complete resolution of symptoms. Age, degree of motor deficit, and duration of symptoms at diagnosis were not associated with complete resolution. While symptomatic patients were more likely to undergo upfront laminectomy, laminectomy was not associated with improvement of motor symptoms. Administration of additional chemotherapy beyond initial treatment assigned per protocol to achieve the treatment end point was not associated with achieving symptom resolution.

conclusionPatients presenting with motor deficits due to intraspinal tumor had excellent survival and favorable neurologic outcomes, with the majority reporting complete resolution of motor symptoms regardless of severity and duration of symptoms at diagnosis or neurosurgical intervention. Prompt diagnosis and initiation of first-line chemotherapy treatment remain priority, while neurosurgical intervention should be reserved for patients with rapid neurologic deterioration. Biology-based therapy and tumor response should continue to be used to maintain favorable outcomes.

Indexed as

NeuroblastomaAdolescentChildChild, PreschoolFemaleHumansInfantMaleProspective StudiesSpinal Cord CompressionSpinal Cord NeoplasmsSpinal Neoplasmsintermediate risklaminectomyneuroblastomaneurologicparalysisscoliosisspinal cord compression

Identifiers

PMID39502014
PMCPMC11792557

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.